BACKGROUND: Cytokine receptor-like factor 2 (CRLF2) has been shown to play a role in the pathogenesis of acute lymphoblastic leukemia (ALL). Studies have examined the relationship between CRLF2 alterations such as over-expression or deregulation and clinical outcome in childhood ALL, but the results are conflicting. This meta-analysis aimed to explore the association between CRLF2 alterations and survival of pediatric patients with ALL. METHODS: Electronic databases updated to March 2014 were searched for relevant studies. A meta-analysis was made of twelve studies including 5945 patients to evaluate the prognostic significance of CRLF2 alterations on survival in childhood ALL. Hazards ratios (HRs) with 95% confidence intervals (CIs) were pooled across the studies using a fixed-effects model. RESULTS: CRLF2 over-expression in childhood ALL was associated with poor prognosis in terms of relapse-free survival (RFS; HR=1.70, 95% CI=1.28-2.24, P=0.000), event-free survival (EFS; HR=1.78, 95% CI=1.05-3.01, P=0.032), and overall survival (OS; HR=2.28, 95% CI=1.42-3.65, P=0.001). The combined data also suggested that CRLF2 deregulation in childhood ALL was correlated with poor EFS (HR=1.95, 95% CI=1.46-2.61, P=0.000), RFS (HR=2.20, 95% CI=1.53-3.18, P=0.000), and OS (HR=1.89, 95% CI=1.24-2.87, P=0.003). Subgroup analysis on multivariate HRs showed that CRLF2 deregulation independently predicted a poor prognosis for childhood ALL. CONCLUSIONS: The present meta-analysis reveals that both CRLF2 over-expression and deregulation are associated with poor prognosis in pediatric patients with ALL.
BACKGROUND:Cytokine receptor-like factor 2 (CRLF2) has been shown to play a role in the pathogenesis of acute lymphoblastic leukemia (ALL). Studies have examined the relationship between CRLF2 alterations such as over-expression or deregulation and clinical outcome in childhood ALL, but the results are conflicting. This meta-analysis aimed to explore the association between CRLF2 alterations and survival of pediatric patients with ALL. METHODS: Electronic databases updated to March 2014 were searched for relevant studies. A meta-analysis was made of twelve studies including 5945 patients to evaluate the prognostic significance of CRLF2 alterations on survival in childhood ALL. Hazards ratios (HRs) with 95% confidence intervals (CIs) were pooled across the studies using a fixed-effects model. RESULTS:CRLF2 over-expression in childhood ALL was associated with poor prognosis in terms of relapse-free survival (RFS; HR=1.70, 95% CI=1.28-2.24, P=0.000), event-free survival (EFS; HR=1.78, 95% CI=1.05-3.01, P=0.032), and overall survival (OS; HR=2.28, 95% CI=1.42-3.65, P=0.001). The combined data also suggested that CRLF2 deregulation in childhood ALL was correlated with poor EFS (HR=1.95, 95% CI=1.46-2.61, P=0.000), RFS (HR=2.20, 95% CI=1.53-3.18, P=0.000), and OS (HR=1.89, 95% CI=1.24-2.87, P=0.003). Subgroup analysis on multivariate HRs showed that CRLF2 deregulation independently predicted a poor prognosis for childhood ALL. CONCLUSIONS: The present meta-analysis reveals that both CRLF2 over-expression and deregulation are associated with poor prognosis in pediatric patients with ALL.
Authors: Andishe Attarbaschi; Maria Morak; Gunnar Cario; Giovanni Cazzaniga; Hannah M Ensor; Truus te Kronnie; Jutta Bradtke; Georg Mann; Elena Vendramini; Chiara Palmi; Claire Schwab; Lisa J Russell; Martin Schrappe; Valentino Conter; Christopher D Mitchell; Sabine Strehl; Martin Zimmermann; Ulrike Pötschger; Christine J Harrison; Martin Stanulla; Renate Panzer-Grümayer; Oskar A Haas; Anthony V Moorman Journal: Br J Haematol Date: 2012-07-23 Impact factor: 6.998
Authors: Charles G Mullighan; J Racquel Collins-Underwood; Letha A A Phillips; Michael G Loudin; Wei Liu; Jinghui Zhang; Jing Ma; Elaine Coustan-Smith; Richard C Harvey; Cheryl L Willman; Fady M Mikhail; Julia Meyer; Andrew J Carroll; Richard T Williams; Jinjun Cheng; Nyla A Heerema; Giuseppe Basso; Andrea Pession; Ching-Hon Pui; Susana C Raimondi; Stephen P Hunger; James R Downing; William L Carroll; Karen R Rabin Journal: Nat Genet Date: 2009-10-18 Impact factor: 38.330
Authors: Anja Möricke; Alfred Reiter; Martin Zimmermann; Helmut Gadner; Martin Stanulla; Michael Dördelmann; Lutz Löning; Rita Beier; Wolf-Dieter Ludwig; Richard Ratei; Jochen Harbott; Joachim Boos; Georg Mann; Felix Niggli; Andreas Feldges; Günter Henze; Karl Welte; Jörn-Dirk Beck; Thomas Klingebiel; Charlotte Niemeyer; Felix Zintl; Udo Bode; Christian Urban; Helmut Wehinger; Dietrich Niethammer; Hansjörg Riehm; Martin Schrappe Journal: Blood Date: 2008-02-19 Impact factor: 22.113
Authors: C H Pui; F G Behm; J R Downing; M L Hancock; S A Shurtleff; R C Ribeiro; D R Head; H H Mahmoud; J T Sandlund; W L Furman Journal: J Clin Oncol Date: 1994-05 Impact factor: 44.544
Authors: Arian van der Veer; Esmé Waanders; Rob Pieters; Marieke E Willemse; Simon V Van Reijmersdal; Lisa J Russell; Christine J Harrison; William E Evans; Vincent H J van der Velden; Peter M Hoogerbrugge; Frank Van Leeuwen; Gabriele Escherich; Martin A Horstmann; Leila Mohammadi Khankahdani; Dimitris Rizopoulos; Hester A De Groot-Kruseman; Edwin Sonneveld; Roland P Kuiper; Monique L Den Boer Journal: Blood Date: 2013-08-23 Impact factor: 22.113
Authors: Maria Morak; Andishe Attarbaschi; Susanna Fischer; Christine Nassimbeni; Reinhard Grausenburger; Stephan Bastelberger; Stefanie Krentz; Gunnar Cario; David Kasper; Klaus Schmitt; Lisa J Russell; Ulrike Pötschger; Martin Stanulla; Conny Eckert; Georg Mann; Oskar A Haas; Renate Panzer-Grümayer Journal: Blood Date: 2012-10-22 Impact factor: 22.113